Skip to main content
SpringerLink
Log in

Dermatologic Adverse Effects of Anticancer Therapy III: Targeted and Immunotherapies

  • Chapter
  • First Online:
Dermato-Oncology Study Guide

Abstract

Targeted and immunotherapies comprise two of the most promising and expanding classes of agents in oncology. This chapter reviews clinical indications for targeted and immunotherapies, and describes their corresponding associated dermatologic adverse effects (DAEs) in these settings. For each medication discussed, a clinical synopsis is provided which showcases incidence, natural course, clinical features, and management of potential mucocutaneous reactions. This chapter is designed to assist clinicians in anticipating, recognizing, and managing the dermatologic manifestations of these increasingly utilitzed therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol. 2014;21(1):19–26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Oser MG, Jänne PA. A severe photosensitivity dermatitis caused by crizotinib. J Thorac Oncol. 2014;9(7):e51–3.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114(3):485–93.

    Article  PubMed  CAS  Google Scholar 

  4. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22(9):1039–48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, Chen ST. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep. 2018;4(5):452–4.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Widmer S, Grossman M. Chemotherapy patient with Stevens-Johnson syndrome presents to the emergency department: a case report. Am J Emerg Med. 2018;36(7):1325.e3–4.

    Article  Google Scholar 

  7. Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016;26(3):232–9.

    Article  PubMed  CAS  Google Scholar 

  8. Gey A, Milpied B, Dutriaux C, Mateus C, Robert C, Perro G, Taieb A, Ezzedine K, Jouary T. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction. J Eur Acad Dermatol Venereol. 2016;30(1):178–9.

    Article  PubMed  CAS  Google Scholar 

  9. Gupta M, Huang V, Linette G, Cornelius L. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption. Arch Dermatol. 2012;148(8):966–8.

    Article  PubMed  Google Scholar 

  10. Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol. 2014;32(14):e54–6.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012;25(5):569–72.

    Article  PubMed  CAS  Google Scholar 

  12. Anforth R, Fernandez-Penas P. BRAF inhibitor induced verrucal keratosis. Am J Dermatopathol. 2014;36(2):192.

    Article  PubMed  Google Scholar 

  13. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.

    Article  PubMed  CAS  Google Scholar 

  14. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, Long GV, Fernandez-Peñas P. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250–4.

    Article  PubMed  Google Scholar 

  16. Pang A, Tan KB, Aw D, Hsieh WS, Goh BC, Lee SC. A case of Sweet’s syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma. Cutan Ocul Toxicol. 2012;31(1):64–6.

    Article  PubMed  CAS  Google Scholar 

  17. Anderson KA, Bartell HL, Olsen EA. Leukonychia related to vorinostat. Arch Dermatol. 2009;145(11):1338–9.

    Article  PubMed  Google Scholar 

  18. Kakar R, Rommel J, McKinley-Grant L, Shenoy AG, DeSimone JA. Hypersensitivity to romidepsin. J Am Acad Dermatol. 2014;70(1):e21–2.

    Article  PubMed  Google Scholar 

  19. Obeid KM, Ferrara R, Sharma M. Cutaneous lesion induced by a subcutaneous administration of bortezomib. Clin Lymphoma Myeloma Leuk. 2012;12(4):284–6.

    Article  PubMed  CAS  Google Scholar 

  20. Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, Zahradova L, Buchler T, Vorlicek J, Hajek R. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151–3.

    Article  PubMed  CAS  Google Scholar 

  21. Kim JS, Roh HS, Lee JW, Lee MW, Yu HJ. Distinct variant of Sweet’s syndrome: bortezomib-induced histiocytoid Sweet’s syndrome in a patient with multiple myeloma. Int J Dermatol. 2012;51(12):1491–3.

    Article  PubMed  Google Scholar 

  22. Murase JE, Wu JJ, Theate I, Cole GW, Barr RJ, Dyson SW. Bortezomib-induced histiocytoid Sweet syndrome. J Am Acad Dermatol. 2009;60(3):496–7.

    Article  PubMed  Google Scholar 

  23. Tanguy-Schmidt A, Avenel-Audran M, Croué A, Lissandre S, Dib M, Zidane-Marinnes M, Moles MP, Hunault-Berger M. [Bortezomib-induced acute neutrophilic dermatosis]. Annales de dermatologie et de venereologie 2009;136(5):443–6.

    Google Scholar 

  24. Thuillier D, Lenglet A, Chaby G, Royer R, Vaida I, Viseux V, Dadban A, Billet A, Christophe O, Chatelain D, Marolleau JP, Lok C, Damaj G. [Bortezomib-induced eruption: sweet syndrome? Two case reports]. Annales de dermatologie et de venereologie 2009;136(5):427–30.

    Google Scholar 

  25. Knoops L, Jacquemain A, Tennstedt D, Theate I, Ferrant A, Van den Neste E. Bortezomib-induced Sweet syndrome. Br J Haematol. 2005;131(2):142.

    Article  PubMed  Google Scholar 

  26. Hayaishi O. Prostaglandin D2 and sleep. Adv Prostaglandin Thromboxane Leukot Res. 1989;19:26–33.

    PubMed  CAS  Google Scholar 

  27. Böckle BC, Baltaci M, Weyrer W, Sepp NT. Bortezomib-induced lupus erythematosus tumidus. Oncologist. 2009;14(6):637–9.

    Article  PubMed  Google Scholar 

  28. Liu L, Zhao N, Xu W, Sheng Z, Wang L. Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. J Hematol Oncol. 2016;9(1):54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Nooka AK. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology. 2013;27(Suppl 3):11–8.

    PubMed  Google Scholar 

  30. Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Investig New Drugs. 2015;33(3):652–63.

    Article  CAS  Google Scholar 

  31. Alloo A, Khosravi H, Granter SR, Jadeja SM, Richardson PG, Castillo JJ, LeBoeuf NR. Ixazomib-induced cutaneous necrotizing vasculitis. Support Care Cancer. 2018;26(7):2247–50.

    Article  PubMed  CAS  Google Scholar 

  32. Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113–125.e5.

    Article  PubMed  CAS  Google Scholar 

  34. Sanmartín O. Skin manifestations of targeted antineoplastic therapy. Curr Probl Dermatol. 2018;53:93–104.

    Article  PubMed  Google Scholar 

  35. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.

    Article  PubMed  CAS  Google Scholar 

  36. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19(1):258–67.

    Article  PubMed  CAS  Google Scholar 

  37. Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, Oro AE, Chang AL. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149(2):242–3.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lam T, Wolverton SE, Davis CL. Drug hypersensitivity syndrome in a patient receiving vismodegib. J Am Acad Dermatol. 2014;70(3):e65–6.

    Article  PubMed  Google Scholar 

  39. Falchi L, Baron JM, Orlikowski CA, Ferrajoli A. BCR signaling inhibitors: an overview of toxicities associated with Ibrutinib and Idelalisib in patients with chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2016;8(1):e2016011.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology. 2017;31(11):821–8.

    PubMed  Google Scholar 

  41. Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. 2015;21(7):1525–9.

    Article  PubMed  CAS  Google Scholar 

  42. Gabriel JG, Kapila A, Gonzalez-Estrada A. A severe case of cutaneous adverse drug reaction secondary to a novice drug: idelalisib. J Investig Med High Impact Case Rep. 2017;5(2):2324709617711463.

    PubMed  PubMed Central  Google Scholar 

  43. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018;93(11):1311–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–98.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141(3):368–70.

    Article  PubMed  Google Scholar 

  47. Ransohoff JD, Kwong BY. Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17(12):834–51.

    Article  PubMed  Google Scholar 

  48. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354(24):2623–4.

    Article  PubMed  CAS  Google Scholar 

  49. Zhang M, Hassan KM, Musiek A, Rosman IS. Ponatinib-induced neutrophilic panniculitis. J Cutan Pathol. 2014;41(7):597–601.

    Article  PubMed  CAS  Google Scholar 

  50. Eber AE, Rosen A, Oberlin KE, Giubellino A, Romanelli P. Ichthyosiform Pityriasis Rubra pilaris-like eruption secondary to Ponatinib therapy: case report and literature review. Drug Saf. 2017;4(1):19.

    Article  Google Scholar 

  51. Butler TW, Waddell JA, Solimando DA. Drug monographs: pomalidomide and ponatinib. Hosp Pharm. 2013;48(8):636–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol. 2013;69(5):e249–50.

    Article  PubMed  Google Scholar 

  53. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.

    Article  PubMed  CAS  Google Scholar 

  54. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC, Mateus C, Robert C. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59–61.

    Article  PubMed  Google Scholar 

  55. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med. 2011;365(17):1649–50.

    Article  PubMed  CAS  Google Scholar 

  56. Wolber C, Udvardi A, Tatzreiter G, Schneeberger A, Volc-Platzer B. Perforating folliculitis, angioedema, hand-foot syndrome—multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges. 2009;7(5):449–52.

    PubMed  Google Scholar 

  57. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886–92.

    Article  PubMed  CAS  Google Scholar 

  58. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61(2):360–1.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anti Cancer Drugs. 2010;21(2):206–9.

    Article  PubMed  CAS  Google Scholar 

  60. Namba M, Tsunemi Y, Kawashima M. Sorafenib-induced erythema multiforme: three cases. Eur J Dermatol. 2011;21(6):1015–6.

    Article  PubMed  CAS  Google Scholar 

  61. Mancano MA. Pancreatitis-associated with riluzole; linezolid-induced hypoglycemia; sorafenib-induced acute generalized exanthematous pustulosis; creatine supplementation-induced thrombotic events; acute pancreatitis associated with quetiapine; hypomagnesemia and seizure associated with rabeprazole. Hosp Pharm. 2014;49(11):1004–8.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443–5.

    Article  PubMed  Google Scholar 

  63. Kim DK, Lee SW, Nam HS, Jeon DS, Park NR, Nam YH, Lee SK, Baek YH, Han SY, Lee SW. A case of sorafenib-induced DRESS syndrome in hepatocelluar carcinoma. Korean J Gastroenterol. 2016;67(6):337–40.

    Article  PubMed  Google Scholar 

  64. Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482–3.

    Article  PubMed  Google Scholar 

  65. Paz C, Querfeld C, Shea CR. Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol. 2011;65(2):452–3.

    Article  PubMed  Google Scholar 

  66. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008;144(11):1525–6.

    Article  PubMed  Google Scholar 

  67. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24(4):396–400.

    Article  PubMed  Google Scholar 

  68. Dean SM, Zirwas M. A second case of Sunitinib-associated pyoderma Gangrenosum. J Clin Aesthet Dermatol. 2010;3(8):34–5.

    PubMed  PubMed Central  Google Scholar 

  69. ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib. Br J Dermatol. 2008;159(1):242–3.

    Article  PubMed  Google Scholar 

  70. Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266–7.

    Article  PubMed  Google Scholar 

  71. Mihara Y, Yamaguchi K, Nakama T, Nakayama G, Kamei H, Ishibashi N, Uchida S, Akagi Y, Ogata Y. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma]. Cancer Chemother 2015;42(2):233–236.

    Google Scholar 

  72. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    Article  PubMed  CAS  Google Scholar 

  73. Kawai A, Araki N, Hiraga H, Sugiura H, Matsumine A, Ozaki T, Ueda T, Ishii T, Esaki T, Machida M, Fukasawa N. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016;46(3):248–53.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Alpuim Costa D, Baptista de Almeida S, Coelho Barata P, Quintela A, Cabral P, Afonso A, Maia Silva J. Pazopanib-induced cutaneous leukocytoclastic vasculitis: an exclusion diagnosis of a multidisciplinary approach. Case Rep Oncol. 2017;10(3):1041–9.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Usui S, Otsuka A, Kaku Y, Dainichi T, Kabashima K. Pyoderma gangrenosum of the penis possibly associated with pazopanib treatment. J Eur Acad Dermatol Venereol. 2016;30(7):1222–3.

    Article  PubMed  CAS  Google Scholar 

  76. Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, Sibaud V. Development of photoonycholysis with vandetanib therapy. Skin Append Disord. 2017;2(3–4):146–51.

    Google Scholar 

  77. Caro-Gutiérrez D, Floristán Muruzábal MU, de la Fuente EG, Franco AP, López Estebaranz JL. Photo-induced erythema multiforme associated with vandetanib administration. J Am Acad Dermatol. 2014;71(4):e142–4.

    Article  PubMed  Google Scholar 

  78. Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, Mateus C, Tomasic G, Wechsler J, Schlumberger M, Robert C. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148(12):1418–20.

    Article  PubMed  Google Scholar 

  79. Yoon J, Oh CW, Kim CY. Stevens-Johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23(Suppl 3):S343–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Ioannidis G, Gkogkou P, Charalampous P, Diamandi M, Ioannou R. Radiation-recall dermatitis with the everolimus/exemestane combination ten years after adjuvant whole-breast radiotherapy. Radiother Oncol. 2014;112(3):449–50.

    Article  PubMed  Google Scholar 

  81. Kurtzman DJ, Oulton J, Erickson C, Curiel-Lewandrowski C. Everolimus-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Dermatitis. 2016;27(2):76–7.

    Article  PubMed  CAS  Google Scholar 

  82. Atzori L, Conti B, Zucca M, Pau M. Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients. J Eur Acad Dermatol Venereol. 2015;29(8):1626–30.

    Article  PubMed  CAS  Google Scholar 

  83. Yee KW, Hymes SR, Heller L, Prieto VG, Welch MA, Giles FJ. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. Leuk Lymphoma. 2006;47(5):926–9.

    Article  PubMed  Google Scholar 

  84. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917–30.

    Article  PubMed  CAS  Google Scholar 

  85. Okuno S, Bailey H, Mahoney MR, Adkins D, Maples W, Fitch T, Ettinger D, Erlichman C, Sarkaria JN. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer. 2011;117(15):3468–75.

    Article  PubMed  CAS  Google Scholar 

  86. Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Dréno B. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology. 2012;224(3):204–8.

    Article  PubMed  CAS  Google Scholar 

  87. Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol. 2011;91(5):584–5.

    Article  PubMed  CAS  Google Scholar 

  88. Bitar C, Farooqui MZ, Valdez J, Saba NS, Soto S, Bray A, Marti G, Wiestner A, Cowen EW. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):698–701.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner A. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, Advani RH. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2018;180(1):164–6.

    Article  PubMed  Google Scholar 

  91. Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol. 2015;1(5):684–6.

    Article  PubMed  Google Scholar 

  92. Stewart J, Bayers S, Vandergriff T. Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. 2018;40(2):e28–9.

    Article  PubMed  Google Scholar 

  93. Sławińska M, Barańska-Rybak W, Sobjanek M, Wilkowska A, Mital A, Nowicki R. Ibrutinib-induced pyoderma gangrenosum. Polskie Archiwum Medycyny Wewnetrznej. 2016;126(9):710–1.

    PubMed  Google Scholar 

  94. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017;56(1):121–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, Frenzel L, Cherquaoui Z, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jeandel PY, Ranta D, Gressin R, Chantepie S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2605–7.

    Article  PubMed  Google Scholar 

  96. Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report. Lung Cancer. 2016;99:66–8.

    Article  PubMed  Google Scholar 

  97. Kimura T, Sowa-Osako J, Nakai T, Ohyama A, Kawaguchi T, Tsuruta D, Ohsawa M, Hirata K. Alectinib-induced erythema multiforme and successful rechallenge with alectinib in a patient with anaplastic lymphoma kinase-rearranged lung cancer. Case Rep Oncol. 2016;9(3):826–32.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Eytan M. Stein et al. “Ivosidenib or Enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial”. Blood. 2017;130(Suppl 1):726.

    Google Scholar 

  99. Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD. Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016;4:47.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Arellano K, Mosley JC, Moore DC. Case report of ipilimumab-induced diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis. J Pharm Pract. 2018;31(2):227–9.

    Article  PubMed  Google Scholar 

  101. Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Prac. 2017;23(8):620–4.

    Article  CAS  Google Scholar 

  102. Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Gormley R, Wanat K, Elenitsas R, Giles J, McGettigan S, Schuchter L, Takeshita J. Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol. 2014;71(5):e211–3.

    Article  PubMed  Google Scholar 

  104. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.

    Article  PubMed  Google Scholar 

  105. Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161–9.

    Article  PubMed  CAS  Google Scholar 

  106. Choi JN. Dermatologic adverse events to chemotherapeutic agents, part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg. 2014;33(1):40–8.

    Article  PubMed  Google Scholar 

  107. Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Therap Adv Med Oncol. 2018;10:1758834017751634.

    Google Scholar 

  108. Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des Devel Ther. 2018;12:2085–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Khokhar MO, Kettle J, Palla AR. Debilitating skin toxicity associated with Pembrolizumab therapy in an 81-year-old female with malignant melanoma. Case Rep Oncol. 2016;9(3):833–9.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Nomura H, Takahashi H, Suzuki S, Kurihara Y, Chubachi S, Kawada I, Yasuda H, Betsuyaku T, Amagai M, Funakoshi T. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. 2017;44(7):818–21.

    Article  PubMed  CAS  Google Scholar 

  112. Laroche A, Alarcon Chinchilla E, Bourgeault E, Doré MA. Erythema nodosum as the initial presentation of nivolumab-induced sarcoidosis-like reaction. J Cutan Med Surg. 2018;22(6):627–9.

    Article  PubMed  Google Scholar 

  113. Lomax AJ, McGuire HM, McNeil C, Choi CJ, Hersey P, Karikios D, Shannon K, van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Fazekas de St Groth B, McGill N. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20(9):1277–85.

    Article  PubMed  CAS  Google Scholar 

  114. Charollais R, Aubin F, Roche-Kubler B, Puzenat E. [Two cases of granuloma annulare under anti-PD1 therapy]. Annales de dermatologie et de venereologie 2018;145(2):116–119.

    Google Scholar 

  115. Shao K, McGettigan S, Elenitsas R, Chu EY. Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol. 2018;45(1):74–7.

    Article  PubMed  Google Scholar 

  116. Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero PL. Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol. 2017;153(7):721–2.

    Article  PubMed  Google Scholar 

  117. Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by Pembrolizumab: a case series. Mayo Clin Proc. 2017;92(7):1158–63.

    Article  PubMed  Google Scholar 

  118. Tjarks BJ, Kerkvliet AM, Jassim AD, Bleeker JS. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. J Cutan Pathol. 2018;45(8):615–8.

    Article  PubMed  Google Scholar 

  119. Zhao CY, Consuegra G, Chou S, Fernández-Peñas P. Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils. Melanoma Res. 2017;27(6):641–4.

    Article  PubMed  Google Scholar 

  120. Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M. A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab. J Immunother Cancer. 2018;6(1):110.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;81:237–9.

    Article  PubMed  CAS  Google Scholar 

  122. Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18–22.

    Article  PubMed  Google Scholar 

  123. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Santa Clara Valley Medical Center, San Jose, CA, USA

    Timothy Dang

  2. University of Iowa Health Care, Iowa City, IA, USA

    Hannah Thompson

  3. Department of Dermatology, University of Iowa Health Care, Iowa, IA, USA

    Vincent Liu

  4. Stanford Health Care; Stanford Medicine, Palo Alto, CA, USA

    Bernice Kwong

Authors
  1. Timothy Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernice Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy Dang .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Iowa Health Care, Iowa, IA, USA

    Vincent Liu

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dang, T., Thompson, H., Liu, V., Kwong, B. (2021). Dermatologic Adverse Effects of Anticancer Therapy III: Targeted and Immunotherapies. In: Liu, V. (eds) Dermato-Oncology Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-53437-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53437-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53436-3

  • Online ISBN: 978-3-030-53437-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation